AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $873K and bought $493K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$380K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 10 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $227.97
- 52-wk high
- $282.15
- High
- $230.97
- 52-wk low
- $186.05
- Low
- $226.18
- Prev close
- $228.07
- Mkt cap
- $15.13B
- P/E
- 17.7x
- Volume
- 926.2K
- Fwd P/E
- 19.8x
- Beta
- 0.48
- P/S
- 14.4x
- P/B
- 8.9x
- Profit margin
- +70.9%
- Op margin
- +65.0%
- ROE
- +118.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ASND filings
Are insiders buying or selling Ascendis Pharma AS (ASND) stock?
Net selling: insiders sold $873K and bought $493K of ASND stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. The largest was Bodenhoff, Mads (SVP & Pao), who sold $811K. The latest filing was on Sep 9, 2026.
Which members of Congress have traded ASND recently?
None. No member of Congress disclosed a ASND trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ASND smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Buys/Adds (3)
- TS
Two Sigma
$81.6M
bought
- MI
Millennium
$71.1M
bought
- BO
Bank of America
$69.5M
bought
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ASND right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in $2.51 a share above what analysts expected.
Earnings per share
$0.78 expected
Reports Nov 11, 2026, in 41 days
Estimates as of Sep 30, 2026
EPS expected
$0.64 to $1.09
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Jun 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|
| What came in | |||
| Revenue | $36.0M | $57.8M | $101.0M |
| Cost of what it sold | $11.5M | $11.2M | $17.5M |
| Gross profit | $24.5M | $46.6M | $83.4M |
| What it spent | |||
| Research and development | $83.5M | $73.5M | $86.6M |
| Sales and admin | $72.3M | $68.1M | $95.6M |
| Other operating costs | $2.0M | $1.7M | $5.4M |
| Total operating expenses | $157.8M | $143.4M | $187.6M |
| What was left | |||
| Operating profit | -$133.3M | -$96.7M | -$104.2M |
| Interest on debt | $19.6M | $25.3M | $44.8M |
| Profit before tax | -$109.2M | -$98.2M | -$93.6M |
| Tax | $229.0K | $1.0M | $1.1M |
| Net profit | -$109.4M | -$99.2M | -$94.6M |
| EBITDA | -$87.5M | -$71.1M | -$44.2M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Long term debt to total equity ratio of Ascendis Pharma A/S – FWB:A710
NeutralSep 25Ascendis Pharma A/S (ASND) Stock Analysis: Exploring a Potential 31.52% Upside in Biotech Sector
BullishSep 22Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
BullishSep 22Novo Nordisk deal ends as Ascendis (NASDAQ: ASND) takes back obesity drug rights, with more programs shifting over
Leans bullishSep 19Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
NeutralSep 18BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $304
BullishSep 17Ascendis Pharma (NASDAQ:ASND): Strong Growth Meets a High-Quality Technical Setup
BullishSep 16Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?
BearishSep 15
Macro
30 macro signals shaping ASND right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results